• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BNT162b2 对 5-11 岁儿童与 COVID-19 相关的急诊科和紧急护理就诊的影响：一项阴性测试设计。

BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design.

机构信息

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.

出版信息

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):177-179. doi: 10.1093/jpids/piad005.

DOI:10.1093/jpids/piad005
PMID:36715070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10112675/
Abstract

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after ≥3 months. A booster improved protection to 77% [53-88].

摘要

在 Kaiser Permanente 南加州医疗系统中，对 5 至 11 岁儿童进行的 1:1 匹配的测试阴性设计研究中（n = 3984），BNT162b2 针对与奥密克戎相关的急诊或紧急护理就诊的有效性在两剂后 3 个月内为 60%[95%CI：47-69]，3 个月后为 28%[8-43]。加强针可将保护作用提高到 77%[53-88]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9d/10112675/13c298cc4db0/piad005_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9d/10112675/13c298cc4db0/piad005_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9d/10112675/13c298cc4db0/piad005_fig1.jpg

相似文献

1
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design.BNT162b2 对 5-11 岁儿童与 COVID-19 相关的急诊科和紧急护理就诊的影响：一项阴性测试设计。
J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):177-179. doi: 10.1093/jpids/piad005.
2
Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.BNT162b2 疫苗在预防 12 至 17 岁青少年因德尔塔和奥密克戎变异株感染而前往急诊科和紧急护理中心就诊方面的有效性。
JAMA Netw Open. 2022 Aug 1;5(8):e2225162. doi: 10.1001/jamanetworkopen.2022.25162.
3
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
4
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.美国大型医疗体系中，针对奥密克戎和德尔塔变异株，BNT162b2 疫苗对住院和急诊科就诊的持久性：一项病例对照研究。
Lancet Respir Med. 2022 Jul;10(7):689-699. doi: 10.1016/S2213-2600(22)00101-1. Epub 2022 Apr 22.
5
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.辉瑞-生物科技 BNT162b2 mRNA 疫苗预防非免疫功能低下 5-17 岁儿童和青少年与 COVID-19 相关的急诊和紧急护理就诊及住院的有效性 - VISION 网络，10 个州，2021 年 4 月-2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):352-358. doi: 10.15585/mmwr.mm7109e3.
6
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.估计 BNT162b2 疫苗对美国 5 至 11 岁儿童感染德尔塔和奥密克戎变异株的有效性。
JAMA Netw Open. 2022 Dec 1;5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
7
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
8
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
9
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
10
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.在奥密克戎毒株占主导期间，既往BNT162b2型新冠疫苗接种与儿童及青少年有症状的新冠病毒感染之间的关联
JAMA. 2022 Jun 14;327(22):2210-2219. doi: 10.1001/jama.2022.7493.

引用本文的文献

1
Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study.在阴性对照研究中，公共卫生和社会措施的强度与SARS-CoV-2疫苗的有效性相关。
medRxiv. 2025 May 8:2025.05.08.25327221. doi: 10.1101/2025.05.08.25327221.
2
Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.新冠大流行期间儿童感染新冠病毒的风险及疫苗接种的作用：一项叙述性综述
Vaccines (Basel). 2024 Aug 29;12(9):989. doi: 10.3390/vaccines12090989.
3
Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness.

本文引用的文献

1
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.估计 BNT162b2 疫苗对美国 5 至 11 岁儿童感染德尔塔和奥密克戎变异株的有效性。
JAMA Netw Open. 2022 Dec 1;5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
2
Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.BNT162b2疫苗在南非针对奥密克戎亚谱系的有效性和持久性
N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.
3
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
解开谜题：SARS-CoV-2 蛋白组中非定义性突变可能影响疫苗效力。
Front Public Health. 2024 Aug 15;12:1386596. doi: 10.3389/fpubh.2024.1386596. eCollection 2024.
4
Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis.BNT162b2疫苗在预防5至11岁儿童COVID-19相关发病和死亡中的有效性：一项系统评价和荟萃分析。
PLOS Glob Public Health. 2023 Dec 4;3(12):e0002676. doi: 10.1371/journal.pgph.0002676. eCollection 2023.
5
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.SARS-CoV-2 奥密克戎变异株：疾病负担、对疫苗有效性的影响以及对变异株适应性疫苗的需求。
Front Immunol. 2023 May 23;14:1130539. doi: 10.3389/fimmu.2023.1130539. eCollection 2023.
BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Aug 11;387(6):525-532. doi: 10.1056/NEJMoa2203209. Epub 2022 Jul 20.
4
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.意大利 2022 年 1 月至 4 月的一项回顾性分析：BNT162b2 疫苗在 5-11 岁儿童中预防 SARS-CoV-2 感染和 COVID-19 重症的效果。
Lancet. 2022 Jul 9;400(10346):97-103. doi: 10.1016/S0140-6736(22)01185-0. Epub 2022 Jul 1.
5
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Jul 21;387(3):227-236. doi: 10.1056/NEJMoa2205011. Epub 2022 Jun 29.
6
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.美国大型医疗体系中，针对奥密克戎和德尔塔变异株，BNT162b2 疫苗对住院和急诊科就诊的持久性：一项病例对照研究。
Lancet Respir Med. 2022 Jul;10(7):689-699. doi: 10.1016/S2213-2600(22)00101-1. Epub 2022 Apr 22.
7
COVID-19, vaccine hesitancy and child vaccination: Challenges from Brazil.新冠疫情、疫苗犹豫与儿童疫苗接种：来自巴西的挑战
Lancet Reg Health Am. 2022 Apr;8:100246. doi: 10.1016/j.lana.2022.100246. Epub 2022 Apr 1.
8
BNT162b2 Protection against the Omicron Variant in Children and Adolescents.BNT162b2 对儿童和青少年奥密克戎变异株的保护效果。
N Engl J Med. 2022 May 19;386(20):1899-1909. doi: 10.1056/NEJMoa2202826. Epub 2022 Mar 30.
9
Effectiveness of BNT162b2 against COVID-19 in adolescents.BNT162b2对青少年新冠病毒肺炎的有效性
Lancet Infect Dis. 2022 May;22(5):581-583. doi: 10.1016/S1473-3099(22)00177-3. Epub 2022 Mar 21.
10
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.2 剂 BNT162b2（辉瑞-生物科技）mRNA 疫苗预防 5-11 岁儿童和 12-15 岁青少年感染 SARS-CoV-2 的效果 - PROTECT 队列，2021 年 7 月至 2022 年 2 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. doi: 10.15585/mmwr.mm7111e1.